A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

NCT04576156 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

327

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelofibrosis

Interventions

DRUG: Imetelstat
DRUG: Best Available Therapy (BAT)

Sponsor

Geron Corporation